Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Geron Corp (GERN)

Geron Corp (GERN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.4200 unch (unch) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.4001 -0.0199 (-1.40%) 18:19 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3600
Day High
1.4400
Open 1.3900
Previous Close 1.4200 1.4200
Volume 6,357,500 6,357,500
Avg Vol 13,821,895 13,821,895
Stochastic %K 74.12% 74.12%
Weighted Alpha -67.67 -67.67
5-Day Change +0.1500 (+11.81%) +0.1500 (+11.81%)
52-Week Range 1.1700 - 5.3400 1.1700 - 5.3400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 878,940
  • Shares Outstanding, K 636,913
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -174,570 K
  • EBIT $ -174 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.66
  • Price/Sales 11.75
  • Price/Cash Flow N/A
  • Price/Book 3.06

Options Overview Details

View History
  • Implied Volatility 142.63% ( -21.04%)
  • Historical Volatility 75.14%
  • IV Percentile 87%
  • IV Rank 25.76%
  • IV High 521.72% on 05/29/24
  • IV Low 11.12% on 07/01/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 825
  • Volume Avg (30-Day) 724
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 85,625
  • Open Int (30-Day) 85,669

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.04
  • Number of Estimates 6
  • High Estimate -0.03
  • Low Estimate -0.05
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +21.37%
on 04/16/25
Period Open: 1.7000
1.7500 -18.86%
on 03/26/25
-0.2800 (-16.47%)
since 03/25/25
3-Month
1.1700 +21.37%
on 04/16/25
Period Open: 3.0100
3.0900 -54.05%
on 02/05/25
-1.5900 (-52.82%)
since 01/24/25
52-Week
1.1700 +21.37%
on 04/16/25
Period Open: 3.5600
5.3400 -73.41%
on 06/12/24
-2.1400 (-60.11%)
since 04/25/24

Most Recent Stories

More News
Why Geron Stock Is Plummeting Today

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.

GERN : 1.4200 (unch)
Geron (GERN) Q4 2024 Earnings Call Transcript

GERN earnings call for the period ending December 31, 2024.

GERN : 1.4200 (unch)
Geron: Q4 Earnings Snapshot

Geron: Q4 Earnings Snapshot

GERN : 1.4200 (unch)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 32.20 (+0.53%)
JNJ : 154.58 (-0.23%)
VRTX : 493.84 (+0.28%)
SNDX : 13.33 (+0.23%)
ABBV : 186.06 (+3.15%)
GERN : 1.4200 (unch)
RHHBY : 39.5200 (-0.58%)
PFE : 22.92 (+0.61%)
NTLA : 8.31 (+1.59%)
BMY : 47.90 (-1.62%)
BIIB : 118.84 (-0.56%)
Geron Stock Rallies More Than 60% in a Year: Here's Why

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...

PBYI : 3.00 (-0.33%)
CSTL : 20.63 (-1.43%)
GERN : 1.4200 (unch)
HALO : 60.49 (+2.09%)
Geron (GERN) Q3 2024 Earnings Call Transcript

GERN earnings call for the period ending September 30, 2024.

GERN : 1.4200 (unch)
Geron: Q3 Earnings Snapshot

Geron: Q3 Earnings Snapshot

GERN : 1.4200 (unch)
Is This Penny Stock With 55% Upside A Buy Now?

This biotech company currently has an approved product on the market. However, there is more to the story than meets the eye.

$SPX : 5,525.21 (+0.74%)
GERN : 1.4200 (unch)
Geron (GERN) Q2 2024 Earnings Call Transcript

GERN earnings call for the period ending June 30, 2024.

GERN : 1.4200 (unch)
Geron: Q2 Earnings Snapshot

Geron: Q2 Earnings Snapshot

GERN : 1.4200 (unch)

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.5333
2nd Resistance Point 1.4867
1st Resistance Point 1.4533
Last Price 1.4200
1st Support Level 1.3733
2nd Support Level 1.3267
3rd Support Level 1.2933

See More

52-Week High 5.3400
Fibonacci 61.8% 3.7471
Fibonacci 50% 3.2550
Fibonacci 38.2% 2.7629
Last Price 1.4200
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective